FOXO Technologies Inc., a company specializing in AI-driven epigenetic applications, has filed a prospectus supplement with the SEC, detailing the issuance of Class A common stock and warrants. The supplement, dated January 23, 2024, updates information from the original prospectus dated May 5, 2023, and includes details on the issuance of up to 10,062,500 shares of Class A common stock upon the exercise of public warrants, 316,250 shares upon the exercise of private warrants, and 1,905,853 shares upon the exercise of assumed warrants. Additionally, the supplement covers the potential offer and resale of up to 5,288,364 shares of Class A common stock by selling securityholders. The company will not receive proceeds from the sale of shares or warrants by the selling securityholders. FOXO Technologies' Class A common...Show More

FOXO Technologies Inc., a company specializing in AI-driven epigenetic applications, has filed a prospectus supplement with the SEC, detailing the issuance of Class A common stock and warrants. The supplement, dated January 23, 2024, updates information from the original prospectus dated May 5, 2023, and includes details on the issuance of up to 10,062,500 shares of Class A common stock upon the exercise of public warrants, 316,250 shares upon the exercise of private warrants, and 1,905,853 shares upon the exercise of assumed warrants. Additionally, the supplement covers the potential offer and resale of up to 5,288,364 shares of Class A common stock by selling securityholders. The company will not receive proceeds from the sale of shares or warrants by the selling securityholders. FOXO Technologies' Class A common stock is listed on the NYSE American LLC under the symbol 'FOXO', and its public warrants are quoted on the OTC Pink Marketplace under 'FOXOW'. The closing prices of the Class A common stock and public warrants as of January 22, 2024, were $0.2950 and $0.0025, respectively. The company has also entered into a material definitive agreement with KR8 AI Inc., involving a Master Software and Services Agreement effective January 12, 2024. The agreement grants FOXO Technologies a license to use KR8 AI Inc.'s products for developing an AI machine learning epigenetic app. The agreement outlines payment terms, including an initial license and development fee, a monthly maintenance fee, and ongoing royalties. FOXO Technologies has issued 1,300,000 shares of common stock to KR8 AI Inc. as part of the agreement.